ArticleCanadian liver journal2025
Hepatitis B virus quantitative surface antigen levels differ by genotype.
Article in Canadian liver journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quantitative HBsAg as a biomarker for disease staging in untreated chronic hepatitis B patients: a cross-sectional study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV) antiviral treatment is guided by HBV DNA levels, liver enzyme values, and fibrosis score. Quantitative hepatitis B surface antigen (qHBsAg) may represent a more cost-effective and less labour-intensive surrogate for HBV DNA. The influence of HBV genotype on qHBsAg has not been well considered. We explored the relationship between HBV DNA and qHBsAg as well as the influence of genotype. Methods: Genotype, HBV DNA, and qHBsAg levels for 138 non-HBV antiviral-treated patients followed at The Ottawa Hospital Viral Hepatitis Program were assessed. Correlations between HBV DNA and qHBsAg as a function of HBV genotype were evaluated. Results: Mean age was 44.5 years; 52.2% were male, 52.3% Asian, and 34.9% Black. Overall median HBV DNA was 2,557 IU/mL. Highest median HBV DNA was in genotypes B (7,899 IU/mL) and C (39,900 IU/mL) and the lowest in genotype E (684 IU/mL). Median qHBsAg overall was 2,000 IU/mL. Highest median qHBsAg was in genotype E (9665 IU/mL) and lowest in genotypes B (300 IU/mL) and C (1,913 IU/mL). HBV DNA-to-qHBsAg ratio differed in direction and magnitude by genotype. HBV DNA and qHBsAg were positively correlated for genotypes A, B, and D but not correlated for genotypes C and E. Age, HBeAg status, and genotype independently predicted HBsAg level and log10 HBV DNA-to-log10 qHBsAg ratio by multi-variable median regression analysis. Conclusions: Median amounts and correlations between HBV DNA and qHBsAg differ in magnitude and direction depending on genotype. This knowledge may be relevant to HBV antiviral treatment guideline development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.